As is the case with blinatumomab and catumaxomab, the administration of BiTEs is linked to CRS, which is indicated by abrupt elevations in the serum amounts of inflammatory cytokines such interleukins-6 (IL-6), tumour necrosis factor (TNF), and interferons (IFNs) (186–188). This evidence concerns the gene IL6 and congenital rubella syndrome.